The FDA's compounding committee recommended six of seven peptides — against its own staff

What PCAC actually is

The Pharmacy Compounding Advisory Committee is an advisory body. It provides independent expert advice to FDA, and its recommendations are non-binding — FDA generally follows them but is not legally required to. This distinction did real work in July: the agency's own scientific staff had committed to a position in writing, and the committee disagreed with it on six of the seven compounds. A recommendation that runs against the agency's own reviewers is still only a recommendation.

The meeting ran at FDA's White Oak campus in Silver Spring, Maryland, on July 23 and 24, with public comment sessions through both days; FDA's meeting page links video of each day. The docket for written comment, FDA-2025-N-6895, closed on July 22, the day before the meeting opened. It had drawn 1,876 comments when we last counted, on July 16.

What a 503A Bulks List vote changes — and what it doesn't

Section 503A of the Federal Food, Drug, and Cosmetic Act sets the conditions under which a drug compounded by a licensed pharmacist or physician is exempt from three requirements that would otherwise apply: current good manufacturing practice, labelling with adequate directions for use, and new drug approval. One of those conditions concerns the bulk drug substance used. A substance qualifies if it has an applicable USP or National Formulary monograph, or is a component of an FDA-approved drug, or appears on a list FDA develops by regulation — the 503A Bulks List.

None of the seven peptides has a USP or NF monograph. None is a component of an FDA-approved drug. That is precisely why the list is the only available route, and why the meeting was held.

So a favourable vote, followed by rulemaking, would mean: a licensed pharmacist could lawfully use that substance to compound a drug for an individual patient with a valid prescription. It would not mean the compound is safe and effective — that is what approval means, and no approval is on the table here. It would not create a legal consumer product. And it would have no effect at all on research-use-only material, which is governed by an entirely separate set of rules.

The three distinctions that keep getting collapsed

Coverage of this meeting — including a good deal of it written by parties who sell peptides — tends to blur three separate things into one. They are not the same, and the gap between them is where most of the confusion about peptide legality lives.

The seven compounds

Each was evaluated as two separate substances — the free base and the acetate salt — because FDA treats them as different active ingredients, and the committee was asked a separate question for each form. That is why seven compounds produced fourteen questions. Published accounts report one result per compound; none reports the two forms of any compound splitting.

The use column matters more than it looks. FDA evaluates a substance in the context of the use proposed for it — so BPC-157 was assessed for ulcerative colitis, not tendon healing, and MOTS-c for obesity and osteoporosis, not longevity. Several of these compounds are popularly used for indications FDA never reviewed.

Read the vote and the briefing on each compound

What FDA staff said, and how uniform it was

Seven documents, running to more than 400 pages, arrive at the same four-part case with remarkable consistency. In every single one:

• Neither form is well characterised. The reasons repeat almost verbatim across the seven: naming conventions that do not follow USAN, INN or IUPAC standards, and missing quality-control data — impurities, aggregates, endotoxins — in both the published literature and the nomination packages, which generally lacked a Certificate of Analysis.
• Immunogenicity risk cannot be assessed. FDA's phrasing is careful and worth reading precisely: it says the information needed to evaluate the risk was not available, so potential risks are unknown. That is not a finding of danger. It is also not a clean bill of health, and it is routinely reported as the latter.
• Approved alternatives already exist for the conditions each was nominated to treat. FDA treats the availability of approved therapy as relevant to the safety criterion.
• The identity problem. Across the seven, FDA repeatedly notes it cannot tell whether the substance in a given published study was the free base or the acetate. That single ambiguity undercuts much of what the literature could otherwise be used to argue.

Where the documents differ is more interesting than where they agree, and the differences are the reason the per-compound pages above exist. Emideltide is the only one FDA credits with genuine historical compounding use — and it is still proposed against. Semax is the only one where FDA says some evidence demonstrated a lack of effectiveness rather than simply failing to establish it. BPC-157 is the only one with adverse-event reports involving compounded product. MOTS-c and KPV have essentially no human data at all.

The withdrawn nominations

Here is a detail that has gone almost entirely unreported, and it changes how the meeting should be read: every one of the seven nominations was withdrawn. FDA evaluated all fourteen substances at its own discretion, using the information from the withdrawn packages.

That is unusual. The normal shape of this process is that a nominator — often a compounding pharmacy or a trade body — puts a substance forward and defends it. Withdrawal is what removed these peptides from Category 2 in April. FDA then chose to evaluate them anyway. The Federal Register notice invited nominators to present in support of their nominations, but the packages FDA is working from are ones their sponsors walked away from.

What we said to watch, and what happened

Before the meeting we named three things that would say more than the tally. Here is how each played out — including the one we got wrong.

Whether the committee would split characterisation from evidence. Largely, it set both aside for a different question. Members in the majority said they were applying the 503A criteria rather than drug-approval standards and would leave individual treatment decisions to prescribers and pharmacists; several argued that the realistic alternative to a compounded peptide is a gray-market one, not none at all. Members voting no pointed to the gaps FDA had documented — thin evidence of effectiveness, poor characterisation — and to the risk that listing would suggest a level of review these substances have not had.

Whether emideltide would be treated differently. It was, but not the way we suggested. We called it a plausible place for the committee to split from staff, because it is the one compound FDA credits with real historical compounding use. Instead it was the only compound on which the committee agreed with staff, rejecting it 6–7, 1 abstention. Dissenting members cited low-quality efficacy evidence, poor characterisation, the availability of approved therapies and the complexity of its dosing. We got that one wrong, and our July 16 preview stays on the record as written.

What would happen to the acetate/free base pairing. FDA did put a separate question for each form. Every published account reports a single result per compound, and none reports a compound whose two forms were treated differently.

What has happened since

Nothing FDA has done since the meeting changes any compound's status. We checked on September 25, 2026:

• FDA's list of substances nominated for 503A compounding — where a move into Category 1 would show up first — is still dated May 14, 2026, and none of the six is in Category 1. (source)
• FDA's meeting page was last updated on August 6. It lists the briefing documents, voting questions, roster and presentations and links video of both days. It carries no minutes, and nothing on what FDA intends to do. (source)
• We found no proposed rule to add any of the six to the list, and legal commentary published as late as September 17 still describes further FDA action as the next required step. (source)

Three paths remain open. FDA can begin notice-and-comment rulemaking to amend the list at 21 CFR 216.23, which means a proposed rule and a public comment period before anything is final. It can place some or all of the six in Category 1 in the meantime — the interim policy's “under evaluation” category, where FDA generally does not act against pharmacies compounding a substance — which some lawyers expect and others caution a favourable vote does not guarantee. Or it can decline: FDA says it generally follows its advisory committees but is not legally bound by them.

Emideltide's position is simpler: the committee agreed with FDA's staff, and it remains off the list. The full write-up of the votes is on the News Wire.

The second meeting

A second PCAC meeting on five more peptides — cathelicidin (LL-37), GHK-Cu, dihexa acetate, melanotan II and pegylated mechano growth factor (PEG-MGF) — is still due before the end of February 2027. As of September 25, 2026, FDA's page for it gives no date: it says the time and location will be scheduled in the coming months. We will cover the briefing documents when they are released, as we did for July; until then, what each of the five will face sets out FDA's own risk statements.

A note on the docket number

The docket closed on July 22, but if you are citing the record, use FDA-2025-N-6895. There is a discrepancy worth knowing about: FDA's meeting web page gives this number in its public-participation section, but a boilerplate paragraph further down the same page cites a different one, FDA-2026-N-2979. That second number does not appear in the Federal Register notice, which carries FDA-2025-N-6895 in its heading, nor on Regulations.gov, where the docket holding the comments is FDA-2025-N-6895. We have seen the incorrect number reproduced on sites that copied FDA's page verbatim. The docket of record is FDA-2025-N-6895.

Related on Grey Peptides